FDA Clears Rise Therapeutics’ IND Application to Initiate a Phase 1 ...
Rise Therapeutics received FDA clearance for its IND application to start a Phase 1 clinical trial of R-2487, a novel oral immunotherapy for rheumatoid arthritis. R-2487 aims to induce regulatory T cells and reset immune balance, targeting the disease's root cause. The trial will assess safety, tolerability, and clinical activity in up to 36 participants.
Reference News
The FDA accepted Rise Therapeutics' IND application for R-2487, a cellular immunotherapy for rheumatoid arthritis, initiating a Phase I trial. The trial will assess R-2487's safety, tolerability, and clinical activity in 36 subjects. Rise Therapeutics aims to validate R-2487 and other drugs for autoimmune diseases, cancer, and inflammation using synthetic biology.
Rise Therapeutics received FDA clearance for its IND application to start a Phase 1 clinical trial of R-2487, a novel oral immunotherapy for rheumatoid arthritis. R-2487 aims to induce regulatory T cells and reset immune balance, targeting the disease's root cause. The trial will assess safety, tolerability, and clinical activity in up to 36 participants.